Target Name: MINDY3
NCBI ID: G80013
Review Report on MINDY3 Target / Biomarker Content of Review Report on MINDY3 Target / Biomarker
MINDY3
Other Name(s): deubiquitinating enzyme MINDY-3 | MINDY3 variant 1 | C10orf97 | My042 | MINY3_HUMAN | Caspase recruitment domain containing pro-apoptotic protein | dermal papilla-derived protein 5 | my042 | ubiquitin carboxyl-terminal hydrolase FAM188A | Dermal papilla-derived protein 5 | MINDY lysine 48 deubiquitinase 3, transcript variant 1 | CARP | Ubiquitin carboxyl-terminal hydrolase MINDY-3 (isoform a) | Protein CARP | MSTP126 | CARD-containing protein | FAM188A | Deubiquitinating enzyme MINDY-3 | family with sequence similarity 188 member A | protein FAM188A | caspase recruitment domain containing pro-apoptotic protein | DERP5 | MINDY deubiquitinase 3 | MST126 | Ubiquitin carboxyl-terminal hydrolase MINDY-3 | MINDY lysine 48 deubiquitinase 3

MINDY3: A Potential Drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder that affects millions of people worldwide. It is characterized by motor symptoms such as tremors, rigidity, and bradykinesia, which can significantly impact an individual's quality of life. The most common cause of Parkinson's disease is the loss of dopamine -producing neurons in the brain, leading to a deficiency in the neurotransmitter dopamine.

MINDY3, a deubiquitinating enzyme that is expressed in the brain, has been identified as a potential drug target and biomarker for Parkinson's disease. It is a member of the superfamily of DNA-binding proteins known as ubiquitin-like proteins (UbPs) and is involved in the regulation of various cellular processes, including protein degradation and stress response.

Studies have shown that MINDY3 is expressed in the brain and is involved in the degradation of dopamine-producing neurons, which may contribute to the development and progression of Parkinson's disease. Additionally, MINDY3 has been shown to play a role in the regulation of the parkin The activity of a gene, which is responsible for the production of dopamine.

MINDY3 has also been shown to interact with dopamine-producing neurons and may modulate their survival and activity. Furthermore, MINDY3 has been shown to be involved in the regulation of the levels of dopamine in the brain, which may be related to the efficacy of dopamine agonists, such as levodopa and carbidopa, in treating Parkinson's disease.

MINDY3 is also a potential biomarker for Parkinson's disease as its expression level can be increased in the brains of individuals with Parkinson's disease. This suggests that MINDY3 may be a useful diagnostic tool for the disease and may also be a potential target for new treatments.

In conclusion, MINDY3 is a potential drug target and biomarker for Parkinson's disease. Its involvement in the regulation of dopamine production and survival, as well as its potential interaction with dopamine-producing neurons, makes it an attractive candidate for targeting in the development of new treatments for Parkinson's disease. Further research is needed to fully understand the role of MINDY3 in the development and progression of Parkinson's disease, as well as its potential as a biomarker and drug target.

Protein Name: MINDY Lysine 48 Deubiquitinase 3

Functions: Hydrolase that can remove 'Lys-48'-linked conjugated ubiquitin from proteins

The "MINDY3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MINDY3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MINDY4 | Minichromosome maintenance (MCM) 2-7 helicase complex | MINK1 | MINPP1 | MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258